Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VEGFR-2-IN-19 (Compound 15b) is a highly efficacious inhibitor of VEGFR2, a receptor involved in angiogenesis. Its mechanism of action involves the induction of cellular apoptosis and elevation of intracellular reactive oxygen species. Due to these properties, VEGFR-2-IN-19 holds promise as an effective anticancer agent [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | VEGFR-2-IN-19 (Compound 15b) is a highly efficacious inhibitor of VEGFR2, a receptor involved in angiogenesis. Its mechanism of action involves the induction of cellular apoptosis and elevation of intracellular reactive oxygen species. Due to these properties, VEGFR-2-IN-19 holds promise as an effective anticancer agent [1]. |
体外活性 | VEGFR-2-IN-19 (Compound 15b) (0-100 μM, 48 h) shows antiproliferative activity against cancer cells [1]. VEGFR-2-IN-19 (0-10 μM, 48 h) inhibits the phosphorylation of VEGFR2 and the Raf/MEK/ERK signaling pathway, induces cell apoptosis, and arrests cell cycle at G0/G1 phase in HT-29 cells [1]. VEGFR-2-IN-19 (0-10 μM, 12 h) increases intracellular reactive oxygen species level in HT-29 cells [1]. Cell Cytotoxicity Assay [1] Cell Line: HT-29 and A549 Concentration: 0-100 μM Incubation Time: 48 h Result: Showed antiproliferative activity with IC 50 values of 3.38±1.3 μM and 0.63±0.04 μM against HT-29 and A549 cells, respectively. Western Blot Analysis [1] Cell Line: HT-29 Concentration: 0, 1, 5, and 10 μM Incubation Time: 48 h Result: Effectively inhibited the phosphorylation of VEGFR2 in dose-dependent manner. Suppressed dose-dependently expression of c-Raf, ERK1/2, and MEK and phosphorylation of ERK1/2 (pERK1/2). Up-regulated caspase-3 and Bax expression, down-regulated Bcl-2 expression. Apoptosis Analysis [1] Cell Line: HT-29 Concentration: 0, 1, 5, and 10 μM Incubation Time: 48 h Result: The total numbers of early and late apoptotic cells were increased significantly relative to that of untreated control cells in dose-dependent manner. Cell Cycle Analysis [1] Cell Line: HT-29 Concentration: 0, 1, 5, and 10 μM Incubation Time: 48 h Result: Increased the population of cells in sub G1 and G0/G1 phase and decreased the population of cells in S phase. |
分子量 | 345.39 |
分子式 | C21H19N3O2 |
CAS No. | 2456315-41-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
VEGFR-2-IN-19 2456315-41-4 Inhibitor inhibitor inhibit